Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis

Jian, Zhongyu; Yuan, Chi; Li, Hong; Zhang, Wei; Wang, Kun‐Jie

doi:10.1007/s11255-020-02536-5

Cited by 5 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We thank Wang and Li for their interest in our recent study [1]. We agree that the limited number of the included studies and heterogeneity among the studies might reduce the comparability of the data and influence the outcome.…”

Section: Editormentioning

confidence: 75%

See 1 more Smart Citation

Reply to the comment on “Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meat-analysis”

Jian

Yuan

et al. 2021

Int Urol Nephrol

Self Cite

View full text Add to dashboard Cite

Section: Editormentioning

confidence: 75%

“…We agree that the limited number of the included studies and heterogeneity among the studies might reduce the comparability of the data and influence the outcome. This point was described in the limitation part, in our original article [1].…”

Section: Editormentioning

confidence: 87%

Reply to the comment on “Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meat-analysis”

Jian

Yuan

et al. 2021

Int Urol Nephrol

Self Cite

View full text Add to dashboard Cite

“…Compared to anticholinergic drugs, mirabegron and vibegron are better tolerated by patients, resulting in improved treatment adherence. 9,32 Mirabegron can inhibit CYP2D6 activity, and drug interactions should be considered during treatment. 33 However, vibegron has no inhibitory effect on CYP enzymes, which is one of its advantages over mirabegron.…”

Section: Publication Biasmentioning

confidence: 99%

“…33 However, vibegron has no inhibitory effect on CYP enzymes, which is one of its advantages over mirabegron. 9 Currently, there are no head-to-head clinical studies comparing the efficacy and safety of the two drugs. Therefore, indirect meta-analysis can provide an evidence-based approach when choosing between the two treatments.…”

Section: Publication Biasmentioning

confidence: 99%

“…The incidences of AEs for mirabegron and vibegron were similar to those observed with placebo, while the incidence of dry mouth appeared to be lower than that of anticholinergic drugs. 8,9 Mirabegron and vibegron are adrenergic beta-3 receptor agonists, but head-to-head comparisons are still lacking. Therefore, indirect treatment comparisons may provide the best available evidence to support informed decisions when deciding between the two treatments.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta‐analysis

Zhang

Huang

et al. 2023

LUTS

View full text Add to dashboard Cite

Objectives: The aim of this study was to indirectly compare the efficacy and safety of mirabegron and vibegron in patients with overactive bladder.Methods: A systematic search was performed on Pubmed, Web of Science, Embase, and the Cochrane Central Register of Controlled Trials databases to identify studies from the date of database inception to January 1, 2022. All randomized controlled trials comparing mirabegron or vibegron with tolterodine, imidafenacin, or placebo were eligible. One reviewer extracted data, and a second reviewer checked. Included trials were assessed for similarity, and networks were developed using Stata 16.0 software. Mean differences for continuous variables and odds ratios for dichotomous variables together with their 95% confidence intervals (CIs) were used to rank treatments and compare the differences, respectively.Results: A total of 11 randomized controlled trials and 10 806 patients were included. For each outcome, results for all licensed treatment doses were included.Both vibegron and mirabegron were more efficacious than placebo at reducing the frequency of micturition, incontinence, urgency, urgency incontinence, and nocturia.Vibegron was more efficacious than mirabegron in reducing mean voided volume/ micturition (95% CI [5.15, 14.98]). Safety outcomes for vibegron and mirabegron were similar to those in the placebo group, except for mirabegron, which had a higher risk of nasopharyngitis and cardiovascular adverse events than placebo.Conclusions: Both drugs seem to be comparable and well tolerated, particularly as direct comparisons are not available. However, vibegron may be more effective than mirabegron in reducing mean voided volume.mirabegron, network meta-analysis, overactive bladder, randomized controlled trials, vibegron | INTRODUCTIONOveractive bladder (OAB) is defined as "urgency, with or without urgency incontinence usually accompanied by frequent micturition and nocturia." 1 OAB pathogenesis is diverse, but in most instances, the underlying cause is unclear. OAB is a common health disorder with a worldwide prevalence in adults of 10%-20%, which has gradually increased. 2,3 OAB is a common urological disease, and it seriously affects the quality of life of patients. Current treatments for OAB include behavioral therapy, pharmacological treatment, minimally

show abstract

Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial

Wada,

Mizunaga,

Abe

et al. 2024

World J Urol

View full text Add to dashboard Cite

Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis

Cited by 5 publications

References 21 publications

Reply to the comment on “Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meat-analysis”

Reply to the comment on “Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meat-analysis”

Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta‐analysis

Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial

Contact Info

Product

Resources

About